Cita NeuroPharmaceuticals

Mississauga, Canada Founded: 1997 • Age: 29 yrs Acquired By Vernalis
Small molecule neuropharmaceuticals are developed and commercialized for neurological disorders.

About Cita NeuroPharmaceuticals

Cita NeuroPharmaceuticals is a company based in Mississauga (Canada) founded in 1997 was acquired by Vernalis in November 2005.. Cita NeuroPharmaceuticals operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.

  • Headquarter Mississauga, Canada
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Vernalis

    (Nov 17, 2005)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Cita NeuroPharmaceuticals

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cita NeuroPharmaceuticals

Cita NeuroPharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Vernalis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Vernalis is engaged in structure-based drug discovery collaborations.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cita NeuroPharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cita NeuroPharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cita Neuropharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cita NeuroPharmaceuticals

Cita NeuroPharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
domain founded_year HQ Location
Biologics platform developed for intracellular delivery in rare diseases.
domain founded_year HQ Location
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
domain founded_year HQ Location
T-cell-based therapies for autoimmune and degenerative diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cita Neuropharmaceuticals

Frequently Asked Questions about Cita NeuroPharmaceuticals

When was Cita NeuroPharmaceuticals founded?

Cita NeuroPharmaceuticals was founded in 1997.

Where is Cita NeuroPharmaceuticals located?

Cita NeuroPharmaceuticals is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.

What does Cita NeuroPharmaceuticals do?

Cita NeuroPharmaceuticals was founded in 1997 in Mississauga, Canada, within the neuropharmaceutical sector. Small molecule drug candidates are developed and commercialized by the company for neurological diseases and disorders. Key products include CNP1512 for Parkinsons disease treatment, CNP3381 for neuropathic pain, and CNP1061 for Alzheimers disease. The company, formerly known as GB Therapeutics, was renamed in 2005 and later acquired by Vernalis. Operations focus on advancing therapies in this field.

Who are the top competitors of Cita NeuroPharmaceuticals?

Cita NeuroPharmaceuticals's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.

Who are Cita NeuroPharmaceuticals's investors?

Cita NeuroPharmaceuticals has 1 investor. Key investors include Vernalis.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available